SR9009 offers a targeted therapeutic approach for PCS1, the most aggressive prostate cancer subtype, through a novel mechanism that involves LXRα activation instead of its originally hypothesized REV-ERB pathway. It inhibits key oncogenic processes such as cell migration, colony formation, and cell cycle progression while inducing apoptosis. The compound selectively downregulates genes in the FOXM1 pathway, known for their role in tumor cell proliferation and survival, including CCNB1, CDK1, and BIRC5. Unlike conventional androgen-deprivation therapies, SR9009 functions independently of androgen receptor signaling, making it a promising candidate for castration-resistant prostate cancer. In vivo experiments confirm its efficacy, showing significant tumor size reduction in xenograft models. The findings highlight SR9009 as an innovative agent capable of tackling therapy-resistant prostate cancers with minimal cytotoxicity to normal prostate cells, paving the way for new treatment paradigms.
Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about SR9009 by Deus Medical, consult with your doctor or healthcare professional.
Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.
Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.
Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.
Home
